Open AccessPharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation
Author(s) -
Senthil Velan Bhoopalan,
Shane J. Cross,
John C. Panetta,
Brandon M. Triplett
Publication year - 2020
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-020-04160-7
Subject(s) - alemtuzumab , ex vivo , hematopoietic cell , pharmacokinetics , medicine , hematopoietic stem cell transplantation , transplantation , in vivo , haematopoiesis , oncology , stem cell , cancer research , biology , microbiology and biotechnology , genetics
Alemtuzumab is a humanized monoclonal antibody against CD52 which is predominantly present on T and B lymphocytes. Alemtuzumab has been used as part of conditioning regimens for prophylaxis against rejection and GVHD. While the mechanism of action is well understood, the pharmacokinetics of this drug in children needed to be studied in more detail especially in the setting of ex vivo T-cell-depleted hematopoietic cell transplantation (HCT).